EN | TR
E-ISSN: 3061-9947
Can Basal Neutrophil to Lymphocyte Ratio Predict the Clinical Outcome of Malign Melanoma Patients?
PDF
Cite
Share
Request
Original Article
VOLUME: 53 ISSUE: 2
P: 317-323
2020

Can Basal Neutrophil to Lymphocyte Ratio Predict the Clinical Outcome of Malign Melanoma Patients?

Acta Haematol Oncol Turc 2020;53(2):317-323
DOI: 10.5505/aot.2020.72325
Umut Varol 1
Gözde Kurttel 2
İbrahim Vedat Bayoğlu 3
Ahmet Alacacıoğlu 4
Ceyhun Varım 3
Utku Oflazoğlu 4
Tarık Salman 4
Yaşar Yıldız 4
Yüksel Küçükzeybek 4
Mustafa Oktay Tarhan 5
1. Department of Medical Oncology, Izmir Democracy University, Izmir
2. Department of Internal Medicine, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir
3. Department of Medical Oncology, Sakarya University Training and Research Hospital, Sakarya
4. Department of Medical Oncology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir
5. Institute of Oncology, Dokuz Eylul University, Izmir
6.
No information available.
No information available
Received Date: 2019-09-18T10:09:39
Accepted Date: 2020-09-04T11:15:14
PDF
Cite
Share
Request

Abstract

INTRODUCTION

Immune system could play an effective role on clinical outcome of the melanoma patients. Neutrophil-to-lymphocyte ratio (NLR) is an indirect indicator for the immune response against to the tumor. So, we aimed to evaluate the prognostic importance of basal NLR in patients with malignant melanoma.

METHODS

We retrospectively reviewed 134 patients with malignant melanoma diagnosed in about an eight year period and 94 patients were included in the study. The values of NLR were assessed at the time of diagnosis. NLR cut-off value was determined as 2.1 by ROC curve. All patients were classified as high and low according to this cut-off value. The prognostic significance of NLR on clinical outcome of the patients was evaluated according to tumor or patient characteristics.

RESULTS

Among 94 patients, 37 were metastatic and 57 had received adjuvant therapy. For all cases, median overall survival (OS) was 83.8 months in NLR low group and 23.8 months in NLR high group (p<0.001). For non-metastatic subgroup, median OS could not be reached in low NLR group and 40.2 months in high NLR group (p=0.031), median disease free survival were 60.8 months and 14.4 months (p=0.038) in NLR low and high group, respectively. There were no correlation between NLR and tumor or patient characteristics except of a higher NLR ratio was found in patients age > 60 (p=0.027).

DISCUSSION AND CONCLUSION

High NLR value showed a strong association with poor prognosis in melanoma patients and it can be used as a marker for prognosis.